- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
Prenoxdiazine is a respiratory drug used to treat asthma and chronic obstructive pulmonary disease (COPD). It is a long-acting beta-agonist (LABA) that works by relaxing the muscles of the airways, allowing more air to flow in and out of the lungs. Prenoxdiazine is typically used in combination with an inhaled corticosteroid (ICS) to provide better control of asthma symptoms. It is available in both oral and inhaled forms, and is often prescribed as a maintenance therapy for long-term control of asthma and COPD.
Prenoxdiazine is a widely used respiratory drug, and is available from many pharmaceutical companies. Some of the major players in the market include GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more